These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20121885)

  • 1. Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome.
    Godoy-Matos AF; Bahia LR; Domingues RC; Tambascia M; Geloneze B; Kraemer-Aguiar LG; Bouskela E
    Diabet Med; 2010 Jan; 27(1):23-9. PubMed ID: 20121885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
    Jucker BM; Schaeffer TR; Haimbach RE; Mayer ME; Ohlstein DH; Smith SA; Cobitz AR; Sarkar SK
    Metabolism; 2003 Feb; 52(2):218-25. PubMed ID: 12601636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
    James AP; Watts GF; Mamo JC
    Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes.
    Nam JS; Nam JY; Yoo JS; Cho M; Park JS; Ahn CW; Cha BS; Lee EJ; Lim SK; Kim KR; Lee HC
    Diabet Med; 2010 Jan; 27(1):30-6. PubMed ID: 20121886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients.
    Ulgen F; Herder C; Kühn MC; Willenberg HS; Schott M; Scherbaum WA; Schinner S
    Arch Physiol Biochem; 2010 May; 116(2):57-62. PubMed ID: 20222849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectopic fat deposition and the metabolic syndrome in obese children and adolescents.
    Cali AM; Caprio S
    Horm Res; 2009 Jan; 71 Suppl 1():2-7. PubMed ID: 19153496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity.
    Sinha R; Dufour S; Petersen KF; LeBon V; Enoksson S; Ma YZ; Savoye M; Rothman DL; Shulman GI; Caprio S
    Diabetes; 2002 Apr; 51(4):1022-7. PubMed ID: 11916921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
    Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
    Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic implications of dietary trans-fatty acids.
    Dorfman SE; Laurent D; Gounarides JS; Li X; Mullarkey TL; Rocheford EC; Sari-Sarraf F; Hirsch EA; Hughes TE; Commerford SR
    Obesity (Silver Spring); 2009 Jun; 17(6):1200-7. PubMed ID: 19584878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between intra-abdominal fat and hypertension in android obese diabetics.
    Sepulveda-Lavados A; Bastard JP; Attal M; Belin MF; Sachon C; Verny C; Grimaldi A
    Ann Med Interne (Paris); 1996; 147(6):393-16. PubMed ID: 9092341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In-vivo 1H-MR spectroscopy: the determination of the intra- and extramyocellular lipid content depending on the insulin effect in the direct offspring of type-2 diabetics].
    Brechtel K; Machann J; Jacob S; Strempfer A; Schick F; Häring HU; Claussen CD
    Rofo; 1999 Aug; 171(2):113-20. PubMed ID: 10506884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome.
    Wajchenberg BL; Giannella-Neto D; da Silva ME; Santos RF
    Horm Metab Res; 2002; 34(11-12):616-21. PubMed ID: 12660870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex and muscle structural lipids in obese subjects - an impact on insulin action?
    Haugaard SB; Vaag A; Høy CE; Madsbad S
    Eur J Clin Invest; 2008 Jul; 38(7):494-501. PubMed ID: 18578691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
    Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
    Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.